{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:07:06Z","timestamp":1793250426087,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CEFALY Technologies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Migraine is one of the most common and debilitating neurological disorders worldwide. External Trigeminal Nerve Stimulation (e-TNS) is a non-pharmacological, non-invasive therapeutic alternative for patients with migraine. The TEAM study was a prospective, multicenter, randomized, double-blind, sham-controlled, Phase 3 trial for 2-h, continuous, e-TNS treatment of a single moderate or severe migraine attack at home. A total of 538 adults meeting the International Classification of Headache Disorders 3rd edition criteria for 2\u20138 migraine headache days per month were recruited and randomized in a 1:1 ratio to 2-h active or sham stimulation. Migraine pain levels and most bothersome migraine-associated symptoms (MBS) were recorded at baseline, 2\u00a0h, and 24\u00a0h using a paper diary. The primary endpoints for the study were pain freedom at 2\u00a0h and freedom from the MBS at 2\u00a0h. The secondary endpoints were pain relief at 2\u00a0h, absence of most bothersome migraine-associated symptoms (MBSs) at 2\u00a0h, acute medication use within 24\u00a0h after treatment, sustained pain freedom at 24\u00a0h, and sustained pain relief at 24\u00a0h. Adverse event data was also collected and compared between groups. Five hundred thirty-eight patients were randomized to either the verum (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009259) or sham (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009279) group and were included in an intention-to-treat analysis. The percentage of patients with pain freedom at 2\u00a0h was 7.2% higher in verum (25.5%) compared to sham (18.3%; p\u2009=\u20090.043). Resolution of most bothersome migraine-associated symptom was 14.1% higher in verum (56.4%) compared to sham (42.3%; p\u2009=\u20090.001). With regards to secondary outcomes, pain relief at 2\u00a0h was 14.3% higher in verum (69.5%) than sham (55.2%; p\u2009=\u20090.001), absence of all migraine-associated symptoms at 2\u00a0h was 8.4% higher in verum (42.5%) than sham (34.1%; p\u2009=\u20090.044), sustained pain freedom and pain relief at 24\u00a0h was 7.0% and 11.5% higher in verum (22.8 and 45.9%) than sham (15.8 and 34.4%; p\u2009=\u20090.039 and .006, respectively). No serious adverse events were reported. Treatment with 2-h e-TNS is a safe and effective, non-invasive, and non-pharmacological alternative for the acute treatment of migraine attacks in an at-home setting.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration<\/jats:bold>\n                    Clinicaltrials.gov Identifier: NCT03465904. Registered 14\/03\/2018.\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT03465904\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT03465904<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-09071-6","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:03:39Z","timestamp":1648155819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)"],"prefix":"10.1038","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02787551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Deena E.","family":"Kuruvilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph I.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart J.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A. L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"10100","key":"9071_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study. Lancet 390(10100), 1211\u20131259 (2017).","journal-title":"Lancet"},{"issue":"5","key":"9071_CR2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/S0317167100118943","volume":"40","author":"I Worthington","year":"2013","unstructured":"Worthington, I. et al. Canadian Headache Society Guideline: Acute drug therapy for migraine headache. Can. J. Neurol. Sci. 40(5), S1\u2013S80 (2013).","journal-title":"Can. J. Neurol. Sci."},{"issue":"7","key":"9071_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby, P. J. et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7), 1894\u20131904. https:\/\/doi.org\/10.1093\/brain\/awz134 (2019).","journal-title":"Brain"},{"issue":"10200","key":"9071_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop, R. et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: A randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200), 737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X (2019).","journal-title":"Lancet"},{"issue":"9","key":"9071_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss, T. et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36(9), 887\u2013898. https:\/\/doi.org\/10.1177\/0333102416653233 (2016).","journal-title":"Cephalalgia"},{"issue":"suppl 1","key":"9071_CR6","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.2004.04105.x","volume":"44","author":"DW Dodick","year":"2004","unstructured":"Dodick, D. W., Martin, V. T., Smith, T. & Silberstein, S. Cardiovascular tolerability and safety of triptans: A review of clinical data. Headache 44(suppl 1), S20\u2013S30 (2004).","journal-title":"Headache"},{"issue":"2","key":"9071_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1517\/14740338.2.2.123","volume":"2","author":"SJ Tepper","year":"2003","unstructured":"Tepper, S. J. & Millson, D. Safety profile of the triptans. Expert Opin. Drug Saf. 2(2), 123\u2013132 (2003).","journal-title":"Expert Opin. Drug Saf."},{"issue":"suppl 2","key":"9071_CR8","first-page":"192","volume":"18","author":"RB Lipton","year":"2011","unstructured":"Lipton, R. B. et al. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention study (P1342). Eur. J. Neurol. 18(suppl 2), 192 (2011).","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"9071_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener, H. C., Holle, D., Solbach, K. & Gaul, C. Medication overuse headache: Risk factors, pathophysiology and management. Nat. Rev. Neurol. 12(10), 575\u2013583 (2016).","journal-title":"Nat. Rev. Neurol."},{"issue":"suppl 2","key":"9071_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton, R. B. & Silverstein, S. D. Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. Headache 55(suppl 2), 103\u2013122 (2015).","journal-title":"Headache"},{"key":"9071_CR11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10194-007-0353-8","volume":"8","author":"TJ Steiner","year":"2007","unstructured":"Steiner, T. J. et al. European principles of management of common headache disorders in primary care. J. Headache Pain 8, S3-47 (2007).","journal-title":"J. Headache Pain"},{"issue":"1","key":"9071_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"International Headache Society","year":"2018","unstructured":"International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1), 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202 (2018).","journal-title":"Cephalalgia"},{"key":"9071_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/j.1526-4610.2011.01917.x","volume":"51","author":"RE Wells","year":"2011","unstructured":"Wells, R. E., Bertisch, S. M., Buettner, C., Phillips, R. S. & McCarthy, E. P. Complementary and alternative medicine use among adults with migraines\/severe headaches. Headache 51, 1087\u20131097 (2011).","journal-title":"Headache"},{"issue":"1","key":"9071_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12906-021-03226-0","volume":"21","author":"DE Kuruvilla","year":"2021","unstructured":"Kuruvilla, D. E., Mehta, A., Ravishankar, N. & Cowan, R. P. A patient perspective of complementary and integrative medicine (CIM) for migraine treatment: A social media survey. BMC Complement Med. Ther. 21(1), 58. https:\/\/doi.org\/10.1186\/s12906-021-03226-0 (2021).","journal-title":"BMC Complement Med. Ther."},{"issue":"2","key":"9071_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40122-015-0039-5","volume":"4","author":"F Riederer","year":"2015","unstructured":"Riederer, F., Penning, S. & Schoenen, J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly\u00ae device for migraine prevention: A review of the available data. Pain Ther. 4(2), 135\u2013147. https:\/\/doi.org\/10.1007\/s40122-015-0039-5 (2015).","journal-title":"Pain Ther."},{"issue":"1","key":"9071_CR16","first-page":"134","volume":"29","author":"PY Gerardy","year":"2009","unstructured":"Gerardy, P. Y., Fabry, D., Fumal, A. & Schoenen, J. A pilot study on supraorbital surface electrotherapy in migraine. Cephalalgia 29(1), 134 (2009).","journal-title":"Cephalalgia"},{"key":"9071_CR17","unstructured":"Komzminski, M. Presented at the 56th annual meeting of the American Headache Society, American Headache Society\u00ae: June 26\u201329, 2014; Hyatt Regency Century Plaza, Los Angeles."},{"issue":"7","key":"9071_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/ner.12623","volume":"20","author":"DE Chou","year":"2017","unstructured":"Chou, D. E., Gross, G. J., Casadei, C. H. & Yugrakh, M. S. External trigeminal nerve stimulation for the acute treatment of migraine: Open label trial on safety and efficacy. Neuromodulation 20(7), 678\u2013683 (2017).","journal-title":"Neuromodulation"},{"issue":"1","key":"9071_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0333102418811573","volume":"39","author":"DE Chou","year":"2019","unstructured":"Chou, D. E. et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized, controlled trial. Cephalalgia 39(1), 3\u201314 (2019).","journal-title":"Cephalalgia"},{"key":"9071_CR20","first-page":"1","volume":"2","author":"D Kuruvilla","year":"2019","unstructured":"Kuruvilla, D., Mann, J., Schoenen, J. & Penning, S. Acute treatment of migraine with external trigeminal nerve stimulation: A pilot trial. Cephalalgia Rep. 2, 1\u20136 (2019).","journal-title":"Cephalalgia Rep."},{"key":"9071_CR21","volume-title":"Migraine: Developing Drugs for Acute Treatment: Guidance for Industry","author":"U.S. Department of Health and Human Services","year":"2018","unstructured":"U.S. Department of Health and Human Services. Migraine: Developing Drugs for Acute Treatment: Guidance for Industry (Center for Drug Evaluation and Research (CDER). Food and Drug Administration, 2018)."},{"issue":"1","key":"9071_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen, P. et al. Guidelines for controlled trials of drugs and migraine: Third edition. A guidance for investigators. Cephalalgia 32(1), 6\u201338 (2012).","journal-title":"Cephalalgia"},{"issue":"6","key":"9071_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"H-C Diener","year":"2019","unstructured":"Diener, H.-C. et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 39(6), 687\u2013710 (2019).","journal-title":"Cephalalgia"},{"issue":"1","key":"9071_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"36","author":"International Headache Society Clinical Trials Subcommittee","year":"2012","unstructured":"International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia 36(1), 6\u201338 (2012).","journal-title":"Cephalalgia"},{"key":"9071_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418796781","author":"C Lauritsen","year":"2018","unstructured":"Lauritsen, C. & Silberstein, S. Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review. Cephalalgia https:\/\/doi.org\/10.1177\/0333102418796781 (2018).","journal-title":"Cephalalgia"},{"key":"9071_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2377-11-135","volume":"11","author":"M Piquet","year":"2011","unstructured":"Piquet, M., Balestra, C., Sava, S. L. & Schoenen, J. E. Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects. BMC Neurol. 11, 135 (2011).","journal-title":"BMC Neurol."},{"issue":"11\u201312","key":"9071_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/03331024211010413","volume":"41","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli, C. et al. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia 41(11\u201312), 1135\u20131151. https:\/\/doi.org\/10.1177\/03331024211010413 (2021).","journal-title":"Cephalalgia"},{"issue":"8","key":"9071_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1212\/WNL.0b013e3182825174","volume":"80","author":"E Asano","year":"2013","unstructured":"Asano, E. & Goadsby, P. J. How do we fashion better trials for neurostimulator studies in migraine?. Neurology 80(8), 694. https:\/\/doi.org\/10.1212\/WNL.0b013e3182825174 (2013).","journal-title":"Neurology"},{"issue":"7","key":"9071_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/head.13115","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton, R. B. et al. Allodynia is associated with initial and sustained response to acute migraine treatment: Results from the American Migraine Prevalence and Prevention Study. Headache J. Head Face Pain 57(7), 1026\u20131040 (2017).","journal-title":"Headache J. Head Face Pain"},{"issue":"20","key":"9071_CR30","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1001\/jama.284.20.2599","volume":"284","author":"RB Lipton","year":"2000","unstructured":"Lipton, R. B. et al. Stratified care vs step care strategies for migraine: The Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 284(20), 2599\u20132605. https:\/\/doi.org\/10.1001\/jama.284.20.2599 (2000).","journal-title":"JAMA"},{"issue":"9","key":"9071_CR31","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers, S. et al. EFNS guideline on the drug treatment of migraine\u2014Revised report of an EFNS task force. Eur. J. Neurol. 16(9), 968\u2013981 (2009).","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"9071_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12883-017-0869-3","volume":"17","author":"M Vikelis","year":"2017","unstructured":"Vikelis, M. et al. Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: A prospective exploratory clinical study. BMC Neurol. 17(1), 97. https:\/\/doi.org\/10.1186\/s12883-017-0869-3 (2017).","journal-title":"BMC Neurol."},{"issue":"1","key":"9071_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1129-2377-14-95","volume":"14","author":"D Magis","year":"2013","unstructured":"Magis, D., Sava, S., d\u2019Elia, T. S., Baschi, R. & Schoenen, J. Safety and patients\u2019 satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly\u00ae device in headache treatment: A survey of 2,313 headache sufferers in the general population. J. Headache Pain 14(1), 95. https:\/\/doi.org\/10.1186\/1129-2377-14-95 (2013).","journal-title":"J. Headache Pain"},{"key":"9071_CR34","unstructured":"CEFALY Technologies. CEFALY DUAL operation manual. Retrieved March 30, 2021. https:\/\/www.cefaly.ch\/media\/pdf\/e2\/c6\/3d\/34077-Manuel-Cefaly-Dual-V02-EN-02-06-07-2018.pdf (2018)."},{"issue":"1","key":"9071_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-018-0933-4","volume":"19","author":"D Vuralli","year":"2018","unstructured":"Vuralli, D., Ayata, C. & Bolay, H. Cognitive dysfunction and migraine. J. Headache Pain 19(1), 1\u201314 (2018).","journal-title":"J. Headache Pain"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09071-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:58:02Z","timestamp":1669319882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09071-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9071"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09071-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Deena Kuruvilla has received consulting fees from Amgen, Lily, Allergan, and GLG Consulting Group. Dr Joseph Mann has no conflicting interests. Dr. Stewart Tepper reports grants for research (no personal compensation) from Allergan\/Abbvie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano, consultant and\/or Advisory Boards (honoraria) from Aeon, Allergan\/Abbvie, Alphasights, Amgen, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting ClearView Healthcare Partners, CoolTech, CRG, Currax, DRG, Eli Lilly, ExpertConnect, FCB Health, GLG, Guidepoint Global, Health Science Communications, HMP Communications, Impel, InteractiveForums, Krog and Partners, Lundbeck, M3 Global Research, MJH Holdings, Neurolief, Novartis, Palion Medical, Pulmatrix, SAI MedPartners, Satsuma, Spherix Global Insights, Strategy Inc, System Analytic, Taylor and Francis, Teva, Theranica, Unity HA, XOC, and Zosano, salary from Dartmouth-Hitchcock Medical Center, American Headache Society, and Thomas Jefferson University, and CME honoraria from the American Academy of Neurology, American Headache Society, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Peerview, Medical Education Speakers Network, Migraine Association of Ireland, North American Center for CME, The Ohio State University, Physicians\u2019 Education Resource, PlatformQ Education, Primed, Texas Neurological Society, and WebMD\/Medscape. Dr. Amaal J. Starling has received consulting fees from Allergan, Amgen, Axsome Therapeutics, Eli Lilly & Company, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Neurolief, Novartis, Satsuma, Teva, and Theranica Dr. Gregory Panza has no conflicting interests. Dr Michael A.L. Johnson is the Global Director of Medical Affairs for CEFALY Technology. All other authors do not have any competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5110"}}